Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome

European Respiratory Journal

Volumn 35, Issue 1, 2010, Pages 105-111

  Cottin, V ^a   Le Pavec, J ^b   Prevot G ^c   Mal, H ^d   Humbert, M ^b   Simonneau, G ^b   Cordier, J F ^a   Berezne A ^e   Coetmeur D ^e   Danner Boucher, I ^e   Funke, D ^e   Israel Biet, D ^e   Marchand, E ^e   Mouthon, L ^e  

^a UNIVERSITÉ LYON 1   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c SERVICE DE PNEUMOLOGIE   (France)

^d BICHAT HOSPITAL   (France)

^e NONE

Author keywords

Chronic obstructive pulmonary disease; Disproportionate; Emphysema; Pulmonary fibrosis; Pulmonary hypertension; Tobacco smoking

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CARBON MONOXIDE; DIURETIC AGENT; ILOPROST; SILDENAFIL;

ADULT; AGED; AMBIENT AIR; ARTERIAL OXYGEN TENSION; ARTICLE; CLINICAL ARTICLE; DIFFUSION COEFFICIENT; DYSPNEA; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HEART CATHETERIZATION; HEART INDEX; HEART RATE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG VASCULAR RESISTANCE; LUNG VOLUME; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY AIRFLOW; RETROSPECTIVE STUDY; SURVIVAL; WALKING;

AGED; AGED, 80 AND OVER; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYNDROME;

EID: 75149155845     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00038709     Document Type: Article

References (34)

1. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84: 365-369.
2. Doherty MJ, Pearson MG, O'Grady EA, et al. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52: 998-1002.
3. Wells AU, King AD, Rubens MB, et al. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997; 155: 1367-1375.
4. Cottin V, Cordier JF. The syndrome of combined pulmonary fibrosis and emphysema. Chest 2009; 136: 1-2.
5. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586-593.
6. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 698-705.
7. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172: 1146-1152.
8. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399.
9. Patel NM, Lederer DJ, Borczuk AC, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132: 998-1006.
10. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
11. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-663.
12. Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30: 715-721.
13. Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76: 288-294.
14. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194.
15. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531-1536.
16. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385.
17. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650-656.
18. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198.
19. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-15.
20. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
21. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
22. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
23. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest 2004; 126: 14S-34S.
24. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
25. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
26. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
27. Aduen JF, Zisman DA, Mobin SI, et al. Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin Proc 2007; 82: 48-54.
28. Fisher MR, Criner GJ, Fishman AP, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30: 914-921.
29. Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102: 1305-1310.
30. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740.
31. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
32. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a National Registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
33. Treatment of pulmonary hypertension in chronic obstructive pulmonary disease. In: Siafakas NM, ed. Management of Chronic Obstructive Pulmonary Disease. Eur Respir Mon 2006; 38: 313-324.
34. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 78S-92S.